A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants
Latest Information Update: 25 Jan 2026
At a glance
- Drugs Zovaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors QL Biopharmaceutical
Most Recent Events
- 16 Jan 2026 Actual Primary Completion Date is 28 Apr 2023.
- 16 Jan 2026 Status changed from recruiting to completed.
- 12 May 2023 Planned number of patients changed from 32 to 56.